

Obesity Is Global; BP and Cholesterol Are Local

BY JENNIE SMITH

FROM THE LANCET

Body mass index rose in all parts of the globe over the past 3 decades, and the proportion of obese people worldwide doubled.

Meanwhile, mean systolic blood pressure dropped worldwide, and total cholesterol levels stayed roughly the same, but with huge regional differences.

Cholesterol levels fell in some regions, particularly in the United States and other English-speaking nations, and increased in others, such as East Asia, according to three papers by collaborating research teams.

Blood pressure was similarly variable by region, with upward trends in parts of Asia and Africa that were countered by downward trends in North America, Australia, and much of Europe.

"We've got this massive wave of obesity happening, but particularly in English-speaking countries we have had this really large decline [in cholesterol and blood pressure]. The good news is, we are mitigating some of the obesity effects," Majid Ezzati, Ph.D., of Harvard School of Public Health, Boston, and Imperial College London, the papers' senior author, said in an interview. But obesity "is a serious rise that we should become serious about combating."

Dr. Ezzati and colleagues' research, which was funded by the World Health Organization and the Bill and Melinda Gates Foundation, sought to map global trends for the main cardiovascular disease indicators – BMI, systolic blood pressure, and total serum cholesterol – in 199 countries and territories during 1980-2008.

The BMI team used data on 960 country-years with 9.1 million people aged 20 years and older (Lancet 2011 Feb. 4 [doi:10.1016/S0140-6736(10)62037-5]). Dr. Ezzati and colleagues found that in 2008, 9.8% of men and 13.8% of women worldwide were obese (defined as having a BMI greater than 30 kg/m²), compared with 4.8% of men and 7.9% of women in 1980.

Mean BMI worldwide increased by 0.4 per decade for men and 0.5 per decade for women. A group of countries in the tropical Pacific region saw an increase of 2 per decade for women, and higher still for men. A handful of countries in South Asia, sub-Saharan Africa, and Europe, meanwhile, registered very slight or no increases, or even declines.

Among high-income countries, the English-speaking countries – including the United States, the United Kingdom, Australia, and New Zealand – saw some of the most pronounced increases, which put them in sharp contrast to some Western European nations.

The United States had both the highest worldwide BMI among high-income countries (mean, 28 for both men and women) and the highest rise in BMI over 28 years (1.1 per decade), followed by male BMI in the United Kingdom (1 per decade) and Australia (0.9 per decade). In 2008, mean BMI in men was highest in

North America (28.4) and Australia and New Zealand (27.6). Also among high-income countries, the United States, New Zealand, and Australia saw the most gains in female BMI over 30 years, with increases of 1.2 per decade.

Changes in blood pressure and cholesterol in these nations, however, did not correspond to these trends but rather seemed to run counter to them.

The English-speaking countries that

saw substantial increases in BMI also recorded significant decreases in total cholesterol levels and blood pressure over the same period, according to a linked study, suggesting an effect from cholesterol-lowering drugs. And Asian countries, which had some of the world's lowest cholesterol levels in 1980, saw dramatic rises.

The cholesterol study examined published and unpublished records encom-

passing 3 million participants aged 25 years and older in 199 countries (Lancet 2011 Feb. 4 [doi:10.1016/S0140-6736(10)62038-7]). Worldwide, the mean, age-standardized, total serum cholesterol level was 4.64 mmol/L for men and 4.76 mmol/L for women, a slight decrease of 0.1 mmol/L per decade since 1980.

Cholesterol fell in Australia, New Zealand, North America, and Western Europe by 0.19 mmol/L per decade for

An advance in the treatment of postmenopausal osteoporosis



Atelvia™ is a bisphosphonate in a delayed-release formulation and is indicated for the treatment of osteoporosis in postmenopausal women.

Selected Safety Information for Atelvia™ (risedronate sodium) delayed-release tablets

Atelvia™ is contraindicated in patients with an inability to stand or sit upright for at least 30 minutes, hypocalcemia, abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia, or known hypersensitivity to any component of this product. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Atelvia™ therapy. Atelvia™ is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Atelvia™ should be taken in the morning immediately following breakfast, and not under fasting conditions. Atelvia™ and Actonel® (risedronate sodium) contain the same active ingredient and therefore, should not be used concurrently.

Atelvia™, like other bisphosphonates administered orally, can cause local irritation of the upper gastrointestinal (GI) mucosa, sometimes severe. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. Dosing instructions should be followed and caution should be used in patients with upper GI disease. Discontinue use if new or worsening symptoms occur. There have also been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates.

Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including risedronate. Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive

men and by 0.21 mmol/L for women.

However, levels remained high in these regions, with a mean of 5.24 for men and 5.23 for women in 2008, with Germany, Greenland, and Iceland having mean, age-standardized levels of 5.5 or greater.

Mean total cholesterol increased in East and Southeast Asia by 0.08 mmol/L per decade in men and by 0.09 mmol/L per decade in women, and was lowest in sub-Saharan Africa at 4.08 for men and 4.27 for women. Cholesterol levels in Japan, which were relatively low in 1980, were close to levels in Western Europe

in 2008. Singapore and China also registered substantial increases.

Globally, the news on blood pressure was also mixed. Mean, age-standardized, systolic blood pressure decreased by 0.8 mm Hg per decade in men and by 1.0 mm Hg per decade in women since 1980, with Western Europe, Australia, New Zealand, and North America seeing steep declines, according to a study of 5.4 million people aged 25 years and older in 199 countries. (Lancet 2011 Feb. 4 [doi:10.1016/S0140-6736(10)62036-3])

However, blood pressure rose in the tropical Pacific, East Africa, and South

and Southeast Asia for both sexes, and in West Africa for women in the same period. Female systolic blood pressure was highest in some East and West African countries in 2008, with means of 135 mm Hg or greater – numbers that, the investigators noted, were not unlike those seen in Europe and North America at the beginning of the study period in 1980.

“The decline we have seen is [primarily] in high-income countries and also parts of Latin America, so really we are dividing the world into the high-income nations that are mitigating the effects,” Dr. Ezzati said. “Middle-income coun-

tries, such as those in Latin America, have shown that they can do it, too, but in lower-income countries the infrastructure is really absent.”

The good news on blood pressure and cholesterol, he said, should be interpreted with caution. With drug interventions, “we are either mitigating or delaying the effects of obesity – we don’t know,” he said.

Dr. Ezzati and colleagues are now working on a diabetes study of similar global scope.

Two researchers reported holding stock in Johnson & Johnson and Pfizer. ■

Introducing New *Enteric-Coated* Atelvia™ for

Efficacy Without the Wait

The only oral bisphosphonate that eliminates the waiting time to eat or drink¹⁻⁴

☪ Dosed immediately after breakfast, once weekly¹

NEW

Enteric-Coated

Atelvia™ 35 mg
(risedronate sodium) delayed-release tablets

Efficacy Without the Wait

dental surgery to treat ONJ may exacerbate the condition. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan (including the consideration of discontinuation of bisphosphonate therapy) of each patient based on individual benefit/risk assessment.

Most common adverse reactions reported in >5% of patients treated with Atelvia™ include: diarrhea, influenza, arthralgia, back pain, and abdominal pain. Hypersensitivity reactions (angioedema, generalized rash and bullous skin reactions, some severe), and eye inflammation (iritis, uveitis) have been reported rarely.

References: 1. Atelvia™ [package insert]. Rockaway, NJ: Warner Chilcott (US), LLC; October 2010. 2. Boniva® [package insert]. South San Francisco, CA: Genentech USA, Inc.; January 2010. 3. Fosamax® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; March 2010. 4. Actonel® [package insert]. Mason, OH: Warner Chilcott Pharmaceuticals Inc.; March 2010.

Please see Brief Summary of Full Prescribing Information on the following page. Full Prescribing Information, which includes the Patient Information, is available at www.atelvia.com.

Atelvia™ is a trademark of Warner Chilcott Company, LLC.

Actonel® is a registered trademark of Warner Chilcott Company, LLC.

